drugset / Trial / NCT04842812
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Phase 1
Recruiting
40 enrolled
Second Affiliated Hospital of Guangzhou Medical University
Guangdong Zhaotai InVivo Biomedicine Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2029-12-31
- Completion
- 2035-01-01